Homocysteine increases the risk associated with hyperlipidaemia

European Journal of Preventive Cardiology

Volumn 16, Issue 2, 2009, Pages 150-155

  Daly, Caroline ^a   Fitzgerald, Anthony P ^b   O'callaghan, Patrick ^c   Collins, Patrick ^d   Cooney, Marie Therese ^c   Graham, Ian M ^c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

cholesterol; homocysteine; lipoproteins; paraoxonase; vascular disease

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; APOA1 PROTEIN, HUMAN; BIOLOGICAL MARKER; LIPID;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLITE; OXIDATION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; EUROPE; MIDDLE AGED; MULTICENTER STUDY; PILOT STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; UPREGULATION;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EUROPE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PILOT PROJECTS; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES; UP-REGULATION;

EID: 67449092930     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32831e1185     Document Type: Article

References (20)

1. O'Callaghan P, Fitzgerald A, Fogarty J, Gaffney P, Hanbidge M, Boran G, et al. New and old cardiovascular risk factors: C-reactive protein, homocysteine, cysteine and von Willebrand factor increase risk, especially in smokers. Eur J Cardiovasc Prev Rehabil 2005; 12: 542–547.
2. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
3. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2):S1–S113.
4. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998; 5: 229–232.
5. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775–1781.
6. Homocysteine Studies Collaboration. Homocysteine and risk of ishemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015–2022.
7. Virtanen J, Voutilainen S, Happonen P, Alfthan G, Kaikkonen J, Mursu J, et al. Serum homocysteine, folate and risk of stroke: Kuopio Ischemic Heart Disease Risk Factor (KIHD) Study. Eur J Cardiovasc Prev Rehabil 2005; 12: 369–375.
8. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230–236.
9. Stubbs PJ, Al-Obaidi MK, Conroy RM, Collinson PO, Graham IM, Noble IM. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 2000; 102: 605–610.
10. O'Callaghan P, Meleady R, Fitzgerald T, Graham I. Smoking and plasma homocysteine. Eur Heart J 2002; 23: 1580–1586.
11. Naruszewicz M, Mirkiewicz E, Olszewski A, Cully KM. Thiolaction of low density lipid by homocysteine causes increased aggregation and altered inerection with cultured macrophages. Nutr Metab Cardiovasc Disc 1994; 4: 70–77.
12. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 1997; 272: 1935–1942.
13. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999; 13: 2277–2283.
14. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000; 275: 3957–3962.
15. Salonen JT, Malin R, Tuomainen TP, Nyyssonen K, Lakka TA, Lehtimaki T. Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study. Br Med J 1999; 319: 487–489.
16. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007; 370: 1829–1839.
17. Walldius G, Jungner I, Holme I, Aastveit A, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026–2033.
18. Bazzano L, Rynolds K, Holder K, He J. Effect of folic acid supplementation on risk of cardiovascular diseases. JAMA 2006; 296: 2720–2726.
19. Vitamins Trialists' Collaboration. Homocysteine-lowering trials for the prevention of cardiovascular events: a review of the design and power of the large randomised trials. Am Heart J 2006; 151: 282–287.
20. SEARCH Collaborative Group. Bowman L, Armitage J, Bulbulia R, Parish S, Collins R. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomised trial among 12 064 myocardial infarction survivors. Am Heart J 2007; 154: 815–823.